Weekly Report: what happened at TPST last week (0708-0712)?
Weekly Report · 10h ago
Peek Under The Hood: IWC Has 48% Upside
NASDAQ · 07/08 14:22
Weekly Report: what happened at TPST last week (0701-0705)?
Weekly Report · 07/08 11:30
$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Allied Gaming & Entertainment Inc. And Archer Aviation are recent notable insider transactions for penny stocks. Archer Aviation acquired a total of 17,401,153 shares at an average price of $3.16.
Benzinga · 07/05 13:10
Weekly Report: what happened at TPST last week (0624-0628)?
Weekly Report · 07/01 11:31
Weekly Report: what happened at TPST last week (0617-0621)?
Weekly Report · 06/24 11:39
Tempest Therapeutics Price Target Maintained With a $8.00/Share by Piper Sandler
Dow Jones · 06/21 18:02
Piper Sandler Reiterates Overweight on Tempest Therapeutics, Maintains $8 Price Target
Benzinga · 06/21 17:52
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), BioNTech SE (BNTX) and Tempest Therapeutics (TPST)
TipRanks · 06/21 11:10
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
The Dow Jones index gained more than 300 points on Thursday. Energy shares jumped by 2% and information technology shares fell by 1.1%. The EIA said stocks of crude oil in the U.S. Declined by 2.547 million barrels in the week ending June 14. European shares closed higher today and Asian markets closed mixed.
Benzinga · 06/20 18:35
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. Fell 7.8% to $116.37 on Thursday. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down 20.2% year-on-year. MGO Global, Inc. Shares jumped 222.8%.
Benzinga · 06/20 17:26
12 Health Care Stocks Moving In Thursday's Intraday Session
Molecular Partners stock rose 39.1% to $11.07 during Thursday's regular session. Zentalis Pharma (NASDAQ:ZNTL) shares rose 36.83% during the session. Femasys stock increased by 28.27% and SeaStar Medical Holding shares rose 18.68%.
Benzinga · 06/20 16:32
Gold Rises 1%; Accenture Shares Surge After Q3 Results
U.S. Stocks traded mostly higher midway through trading on Thursday. The Dow Jones gained over 50 points on Thursday and the NASDAQ rose. Energy shares jumped by 1.5% and real estate shares fell by 0.2%. Accenture Plc reported third-quarter fiscal 2024 results. Asian markets closed mixed in Asia Pacific markets.
Benzinga · 06/20 16:00
Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
Dow Jones · 06/20 15:33
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Benzinga · 06/20 15:22
Tempest falls after new trial data for liver cancer therapy
Tempest Therapeutics, Inc. Shares drop after new trial data for liver cancer therapy. The company updated data from an ongoing trial of amezalpat as a first-line combination therapy for those with hepatocellular carcinoma. Patients who received the amez alpat combo lived a median of 21 months.
Seeking Alpha · 06/20 14:52
Buy Rating Affirmed for Tempest Therapeutics on Promising Amezalpat Clinical Trial Results
TipRanks · 06/20 14:15
What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Tempest Therapeutics Inc (NASDAQ:TPST) announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2. The drug candidate delivered a six-month improvement in median overall survival advantage in patients with hepatocellular carcinoma.
Benzinga · 06/20 13:43
Tempest Therapeutics Announces Data From Phase 1b/2 Study Of Amezalpat (TPST-1120); Shows Six-Month Improvement In Median Overall Survival When Combined With Atezolizumab And Bevacizumab In First-Line Treatment Of Unresectable Or Metastatic Hepatocellular Carcinoma
Company to host webcast conference call today at 8:30am ET. 50% of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio. OS is the primary regulatory endpoint for first-line HCC treatment in patients with cancer.
Benzinga · 06/20 12:53
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
NLS Pharmaceutics (NASDAQ:NLSP) stock is down 22.6% on Thursday after a massive rally on Tuesday. The clinical-stage biopharmaceutical company’s shares closed up 82.1% on Tuesday due to the Juneteenth holiday. More than 2.4 million shares of NLSP stock are changing hands today. There are plenty of other stock market news stories on InvestorPlace for Thursday.
Investorplace · 06/20 12:38
Webull provides a variety of real-time TPST stock news. You can receive the latest news about Tempest Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.